Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • ymc
    Senior Member
    • Mar 2010
    • 496

    #16
    Originally posted by pmiguel View Post
    I don't see a reason for 23andme to store all the read data for a genome sequence. It isn't like their typical user will fire up IGV and peruse the BAM file. [Note: I just noticed that their new "Golden Helix" browser is for that purpose. Pretty crazy...] Storing the data as a diff against some reference sequence would be plenty.

    Anyway, the core of my argument is that storage costs are not likely to be what drove 23andme to do exon sequences, instead of full genomes. Sequence still costs orders of magnitudes more to obtain than to store. Even when total cost to obtain a human genome sequence drops to $1000, storage will still be a minor component of its total cost.

    However, rather than churn through a few more cycles of this dispute, maybe we could look for the price at which we would both agree that storage becomes a substantial part of the cost of obtaining a genome sequence.

    Around $100/genome, the cost of transiently storing the read data will begin to consume enough of a budget that it will be considered a major factor, I think. Of course other computation aspects will also be felt -- CPU time, band width, etc.

    The thing is, below a certain cost per genome, it may no longer make sense to store anything other than the processed data. That is, DNA itself serves as the storage medium if additional information needs to be gleaned. Or, in other words, the information is already stored in the primary structure of the DNA. We are really just paying to "down convert" it from molecular to digital storage.

    Note that as long as the price of obtaining sequence continues to fall at a rate below the rate at which cost to store sequence decreases, the problem of storing the digital form only gets harder. So that is why that even if I disagree about storage being a major factor in the cost of a $1000 genome, I agree that it does become a major factor at $100/genome.

    Of course that leaves us 10-fold from agreeing with one another. But that is, nevertheless, a quantitative disagreement, not a qualitative one.

    --
    Phillip
    Thanks for your thoughtful reply. I am just a home-bound NGS hobbyist. Here is another food for thought from someone who works for a big genome center:

    A working guide to the rapidly developing world of Next-Generation DNA sequencing, with an emphasis on bioinformatics.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    21 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    34 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-09-2026, 10:04 AM
    0 responses
    44 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-08-2026, 10:08 AM
    0 responses
    30 views
    0 reactions
    Last Post SEQadmin2  
    Working...